" class="no-js "lang="en-US"> Steven Stice - Medtech Alert
Tuesday, April 16, 2024
Steven Stice

Steven Stice

About Steven Stice

I have more than 25 years of research and development experience in biotechnology and a co-founder of five biotech companies, one which is ArunA Biomedical, the first company to commercialize a product derived from human pluripotent stem cells and cell development that was used to facilitate approval of Pfizer’s current cognitive enhancing pharmaceuticals, and SciStem Inc., which I currently serve as Chief Scientific Officer. Today my research focus is mainly centered on the development of cell-based assays to support high-throughput chemical and compound screening.

I co-chair a seat on REM, Regenerative Engineering and Medicine — a partnership between: Emory University, Georgia Tech and UGA. I play an active leadership role in EBICS, Emergent Behaviors of Integrated Cellular Systems, a NSF Technology Center founded by MIT.

Past political achievement; working with Sen. Johnny Isaskson (R-Ga.) to develop the HOPE Act (Hope Offered through Principled and Ethical Stem Cell Research Act). In 2009 I was appointed by NIH to the Scientific Advisory Board on mapping the human epigenome. Today (2017), I feel honored to be selected to sit on the Scientific Advisory Board for the Food and Drug Administration (FDA).

• 2001, our labs were first in deriving one set of the original human embryonic stem cell lines in collaboration with BresaGen, Inc. (BG01, 02 and 03)
• First cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie).
• 1997 our group produced the first genetically modified embryonic stem cell derived pigs and cattle. This research led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle embryonic stem cells.
• One of only five NIH sponsored sites for training NIH investigators on the propagation, differentiation and use of hESC over a six year period.

Related Story

Aruna Bio Advances Therapeutic Development for Traumatic Brain Injury

June 1 2022

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the […]